EUVIMEDEUVIMED entdecken
Open Access

RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

Sayan Chakraborty iD, Jie Jiang iD, Javier Vinals Camallonga, Dimitris Gazgalis iD, Thomas W Gero iD, Maurício T Tavares iD, Georgia Dittemore iD, Emre Tkacik iD, Tyler S Beyett iD, Dong Man Jang iD, Byung Hak Ha, Felix H Gottlieb iD und 7 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.aee5241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Sayan Chakraborty und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Drug Design, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinase Kinases. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, Dana-Farber Cancer Institute Pediatric Low-Grade Glioma Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal–regulated kinase pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation of MEK by RAF. However, how MEK inhibitor potency varies across the three RAF isoforms remains poorly understood. We profiled seven allosteric MEK inhibitors and observed a notable hierarchy of sensitivity: All most potently inhibited CRAF-driven MEK activation while relatively sparing ARAF-driven activation. We identified point mutations in ARAF and CRAF proximate to the MEK inhibitor binding site that markedly altered inhibitor sensitivity. Using a rational design approach, we developed a more potent inhibitor of ARAF-driven MEK signaling, TWG-07-148. Our cryo–electron microscopy structure shows how this acrylamide-containing analog of MEK inhibitor trametinib covalently targets Cys 514 , a residue unique to ARAF. Our studies highlight the importance of the activating RAF isoform as a determinant of MEK inhibitor sensitivity and provide proof of concept for the development of MEK inhibitors that more effectively block ARAF-driven MEK signaling via covalent targeting of Cys 514 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsDrug DesignProto-Oncogene Proteins c-rafMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins A-rafraf KinasesHumansProtein IsoformsBinding SitesModels, MolecularCryoelectron MicroscopyPyridonesPyrimidinones

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-rafMitogen-Activated Protein Kinase KinasesProtein IsoformsProto-Oncogene Proteins A-raftrametinibraf KinasesPyridonesPyrimidinones

Autor:innen und Institutionen

  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.

ORCID-Profile: Sayan Chakraborty, Jie Jiang, Dimitris Gazgalis, Thomas W Gero, Maurício T Tavares, Georgia Dittemore, Emre Tkacik, Tyler S Beyett, Dong Man Jang, Felix H Gottlieb, Talya Levitz, Rebecca J Metivier, Anna M Schmoker, David A Scott, Hyesung Jeon, Pasi A Jänne, Michael J Eck

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Dana-Farber Cancer Institute Pediatric Low-Grade Glioma Program

Zitieren

APA

Chakraborty, S., Jiang, J., Camallonga, J. V., Gazgalis, D., Gero, T. W., Tavares, M. T., Dittemore, G., Tkacik, E., Beyett, T. S., Jang, D. M., Ha, B. H., Gottlieb, F. H., Levitz, T., Metivier, R. J., Schmoker, A. M., Scott, D. A., Jeon, H., Jänne, P. A., & Eck, M. J. (2026). RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor. Science Advances. https://doi.org/10.1126/sciadv.aee5241

Vancouver

Chakraborty S, Jiang J, Camallonga JV, Gazgalis D, Gero TW, Tavares MT, et al. RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor. Science Advances. 2026. doi:10.1126/sciadv.aee5241

BibTeX
@article{Chakraborty2026,
  author = {Chakraborty, Sayan and Jiang, Jie and Camallonga, Javier Vinals and Gazgalis, Dimitris and Gero, Thomas W and Tavares, Maurício T and Dittemore, Georgia and Tkacik, Emre and Beyett, Tyler S and Jang, Dong Man and Ha, Byung Hak and Gottlieb, Felix H and Levitz, Talya and Metivier, Rebecca J and Schmoker, Anna M and Scott, David A and Jeon, Hyesung and Jänne, Pasi A and Eck, Michael J},
  title = {RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aee5241}
}
Kostenlos starten →